Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma

BACKGROUND: Cabozantinib improved progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) compared with everolimus in patients with advanced renal cell carcinoma (RCC) after prior antiangiogenic therapy in the phase III METEOR trial (NCT01865747). Limited data are av...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Eur J Cancer
Egile Nagusiak: Donskov, Frede, Motzer, Robert J., Voog, Eric, Hovey, Elizabeth, Grüllich, Carsten, Nott, Louise M., Cuff, Katharine, Gil, Thierry, Jensen, Niels Viggo, Chevreau, Christine, Negrier, Sylvie, Depenbusch, Reinhard, Bergmann, Lothar, Cornelio, Izzy, Champsaur, Anne, Escudier, Bernard, Pal, Sumanta, Powles, Thomas, Choueiri, Toni K.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2019
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7521477/
https://ncbi.nlm.nih.gov/pubmed/31887537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2019.10.032
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak